ICE Bioscience is a leading provider of kinase-related services, offering a diverse range of kinase profiles tailored to the unique needs of each program. Built on extensive kinase research and drug-discovery experience, our comprehensive profiling solutions bring versatility and precision to both kinase inhibitor and degrader discovery.
Access over 250 high-activity recombinant kinase proteins ↗ for reliable and consistent assay results.
More than 600 kinase biochemical assays using ADP-Glo and HTRF platforms enable comprehensive analysis.
Kinase panels are typically used to assess the selectivity and activity of candidate compounds against kinases. In early drug discovery, selectivity is closely linked to safety. Comprehensive evaluation of potential compound–kinase interactions can identify possible off-target binding and help reduce the risk of adverse effects and toxicity.
Extensive MoA research services help elucidate kinase biology, compound activity and downstream functional response in inhibitor and degrader programs.
Cell-based NanoBRET target-engagement assays support analysis of kinase interactions, binding and cellular pharmacology.
Measure compound-driven biological response through targeted, kinase-dependent effects on cell growth and survival.
Robust CDX models support studies of kinase-related pathways and therapeutic interventions.
ICE Bioscience supports kinase degrader programs with integrated biochemical, biophysical and cell-based study strategies. Our capabilities can help characterize compound activity, target engagement, degradation-related cellular response and downstream functional effects across the discovery workflow.
Because each degrader program is target- and mechanism-dependent, our scientific team can work with you to define a fit-for-purpose study plan and discuss target-specific feasibility.
Download an overview of our kinase discovery capabilities and service portfolio.
Download brochure ↗Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein with a critical role in cell growth and differentiation. Dysregulation and mutations in EGFR are implicated in multiple cancers, making it a prominent target for cancer therapy. Understanding EGFR molecular mechanisms and oncogenic roles is central to designing effective targeted therapies.
ICE Bioscience has purified multiple proteins for the EGFR family. Our experienced protein team verifies activity for every batch to ensure purity and activity for diverse assay needs.
We offer a comprehensive range of biochemical assays for over 30 EGFR variants and mutants.
Surface Plasmon Resonance (SPR) provides real-time, label-free analysis of interactions between potential therapeutic compounds and EGFR. It enables determination of affinity, kinetics and specificity to identify and optimize lead compounds with high binding efficacy.
Our platform includes more than 1,000 cell lines, including overexpression, stable and gene-edited cell lines. For EGFR, ICE Bioscience has acquired 30 EGFR mutant-related Ba/F3 stable kinase cell lines and provides dedicated Ba/F3 cell-line construction services.
Cell line-derived xenograft (CDX) models are widely used in preclinical testing of drug efficacy, PK/PD correlations and combination therapies, enabling study of mechanisms that inhibit tumor growth and development.
FGFR is a critical drug-discovery target because of its role in cell growth, differentiation and survival. Aberrant FGFR signalling is associated with cancers and developmental disorders; selective modulation of abnormal FGFR signalling can offer therapeutic benefit for FGFR-related conditions.
We offer over 30 FGFR proteins, including multiple mutants, to support advanced research and drug discovery. Robust enzyme-activity assays using ADP-Glo and HTRF platforms enable precise and sensitive measurement of kinase activity, function and inhibition.
Lipid kinases, including PI3K, regulate cellular growth, survival and metabolism by phosphorylating membrane lipids. Dysregulation of lipid-kinase signalling is implicated in cancer, diabetes and cardiovascular disorders. Understanding their molecular mechanisms and regulatory functions supports the design of effective inhibitors and advancement of lipid kinase-associated therapies.
CDKs are critical regulators of the cell cycle and transcription. Dysregulated CDK activity is associated with cancers and proliferative disorders, making selective CDK inhibition an important strategy in drug discovery and cancer treatment.
ICE Bioscience has expressed and purified more than 20 high-purity, high-activity proteins from the CDK family. Our CDK kinase-screening service uses ADP-Glo assays to quantitatively measure ADP production and reflect compound-mediated inhibition of kinase targets.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
